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Aims. To describe the baseline characteristics of an Australian population-based cohort of rheumatoid arthritis (RA) patients
commencing biological therapy. Methods. Descriptive analysis from the Australian Rheumatology Association Database (ARAD).
Results. Up to October 2006, there were 681 RA patients taking biologics enrolled in ARAD. Baseline data were available for
624 (72% female, mean (SD) age 57.0 (12.5) years). Of these, 59.5% reported at least one comorbid condition, most commonly
hypertension (35.7%) and osteoporosis (30.4%); 61 (9.8%) had a history of malignancy (35 nonmelanoma skin, 5 breast, 4 bowel,
5 cervix, 3 melanoma, 3 prostate and 1 each of lip, lung, myeloma, testis, uterus, vagina). Self-reported infections within the
previous 6 months were common (71.5%). Conclusions. History of comorbidities, including recent infections, is common among
AustralianRApatientscommencingbiologics,and10%haveahistoryofmalignancy.Thismayimpactfutureevaluationsofhealth
outcomes among this population, including attribution of adverse events of biologic therapy.
Copyright © 2009 Andrew M. Briggs et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Rheumatoid arthritis (RA) is a chronic, autoimmune,
inﬂammatory joint disease, which if left untreated often
results in progressive and irreversible joint damage and
disability [1]. As well as being associated with premature
mortality, it has a substantial impact upon quality of life,
physical, social and emotional function [2]. In Australia,
2.4% of the population report having RA [3].
Biological drugs (bDMARDs) including etanercept,
inﬂiximab, adalimumab, anakinra, rituximab and abatacept
have been introduced into clinical practice in Australia
and elsewhere with the anticipation that they represent a
signiﬁcant breakthrough in terms of altering the course and
prognosis of RA [4]. Preliminary, uncontrolled Australian
data suggest that after three months of therapy, etanercept
is well tolerated and of beneﬁt for patients with severe
active RA, although its long-term safety and eﬀectiveness
remains uncertain [5]. This uncertainty highlights the need
for careful longitudinal observation in routine clinical care,
ideally using population-based health registries.
Health registries that aim to determine the long-term
safety of new drug therapy including the incidence and risk
factors for adverse events need to consider potential eﬀect2 International Journal of Rheumatology
modiﬁers. Comorbidities are one example of an important
eﬀect modiﬁer at baseline and over time. The impact of
RA is complicated by the relatively high prevalence of
comorbidities such as gastrointestinal disease, malignancy,
infections, osteoporosis and cardiovascular disease [6, 7]
from both iatrogenic and disease-related causes. Notably,
comorbidity has been shown to be a major predictive
factor for health outcomes in patients with RA [2, 8]
withprematuremortalitylargelyattributedtocardiovascular
disease, infection and malignancy [9, 10].
The importance of considering comorbidity is particu-
larly relevant to Australian patients. Australian patients may
have a greater prevalence of comorbidities given the strict
disease status, severity and treatment response requirements,
including multiple previous DMARD use, which need to
be satisﬁed before bDMARDs can be prescribed under
government-subsidised schemes (Table 1). Furthermore, like
other jurisdictions, previous and/or current malignancy is
not an absolute contraindication to prescribing bDMARDs
in Australia [11], although the risk of certain malignancies
may be dissimilar due to diﬀerences in population and
environmentalfactors.Forexample,Australiahasthehighest
incidence of skin cancer in the world [12].
The primary aim of this paper is to outline the baseline
characteristics including history of malignancy and infection
in a population-based cohort of patients commencing
bDMARD therapy for severe, active RA using data from
the Australian Rheumatology Association Database (ARAD)
[13]. ARAD is a national observational database, established
by the Australian Rheumatology Association (ARA) in 2003
preceded by a pilot study that commenced in 2001, to deter-
mine the long-term eﬀectiveness and safety of bDMARDs
for patients with inﬂammatory arthritis in routine clinical
practice.
2. Methods
2.1. ARAD Design. Details about the structure, governance
and content of ARAD have been described previously [13].
Brieﬂy, ARAD is a voluntary registry that collects longitu-
dinal health outcomes data from Australian patients with
inﬂammatory arthritis (RA, psoriatic arthritis, ankylosing
spondylitis and juvenile idiopathic arthritis) treated with
biological drugs as well as a control group of similar patients
who are not receiving biological therapy. Patients are either
referred to ARAD by their treating rheumatologist or they
canself-refer.PatientstakingbDMARDsaremostcommonly
referredtoARADbytheirtreatingrheumatologistatthetime
of initiation of biological therapy but can enrol at any time
andcontrols(thosenotprescribedbiologics)canenrolatany
time. To 11th December 2008, 3025 participants have been
enrolled in ARAD. They include 2366 with RA, 389 with AS,
186 with psoriatic arthritis and 83 with juvenile idiopathic
arthritis. Two hundred and one (75.2%) rheumatologists
from all Australian states and territories have contributed
patients.
Ethical approval for ARAD has been granted by twenty
committees and organisations across Australia (see the
appendix). All participants provide written permission to
be contacted by ARAD investigators and written informed
consent to participate in the registry.
2.2. Data Collection. Data collected from the rheumatologist
at the time of RA patient enrolment include diagnosis
and disease status data (ESR, CRP and joint count (see
Table 1 for PBS deﬁnition of joint count)) and the bDMARD
prescribed (if applicable). All ARAD participants complete
a detailed entry questionnaire and six-monthly follow-up
questionnaires returned in a reply paid envelope. Returned
data are scanned into the database via teleform and subject
to rigorous quality control and data validation processes to
ensure database quality. Data collected from the participants
include: demographic details, disease duration and severity,
self-reported past and current medical history including
cancers and other chronic conditions, use of antirheumatic
drugs, smoking and alcohol history, generic measures of
quality of life including the Short Form-36 (SF-36) (subscale
scores range 0–100, 100 = perfect health) [14], Assessment of
Quality of Life (AQoL) (score range 0-1, 1 = full health) [15]
and European Union Quality of Life (EuroQoL) ([16]a n d
arthritis-speciﬁcdisabilityassessedbytheHealthAssessment
Questionnaire (score range 0–3, 0 = no disability)) [17].
For the purpose of this study, ARAD participants were
included if they had RA according to their rheumatologist,
had enrolled in ARAD prior to October 1, 2006, and had
completed a baseline questionnaire prior to commence-
ment of bDMARD therapy. Baseline characteristics, medical
history and health-related quality of life of RA patients
commencing bDMARDS were extracted from the last
questionnaire completed prior to commencing bDMARD
therapy. Some questions relating to baseline descriptive
variables, comorbidity, and infection were only added to
the baseline questionnaire in January 2006 and so were
unavailable for participants who completed their baseline
questionnaire prior to this time. For this reason, some of
the data summarised in the results is based on a smaller
sample size. Participants with a history of infection within
the previous 6 months were asked to grade them as mild,
moderateorsevere,accordingtoOMERACTguidelines[18].
An operational deﬁnition of the grading system is provided
in the questionnaire (see footnote Table 6 for deﬁnitions).
Current infections were deﬁned as any infection experienced
within the 6 months prior to completing the questionnaire.
2.3. Veriﬁcation of Malignancy. To verify all self-reported
malignancies, the demographic details of all ARAD par-
ticipants were matched to the National Cancer Statistics
Clearing House (NCSCH) and the Victorian State Cancer
Registry (VCR) in 2007. The NCSCH and VCR record details
of all malignancies occurring in Australia (except Victoria)
and Victoria respectively, apart from nonmelanoma skin
cancers. Notiﬁcation of malignancy to the state registries
is mandatory by law and virtual complete ascertainment is
achieved by notiﬁcation from pathology laboratories, hos-
pital medical record departments and by screening of death
certiﬁcates. The International Classiﬁcation of Diseases, 9thInternational Journal of Rheumatology 3
Table 1: Disease status and treatment response criteria needed to be met by Australian patients in order to receive government-subsided
bDMARDs.
Severe and active disease status Failure to achieve an adequate response to treatment
(i) ESR ≥ 25mm/hr and/or CRP ≥ 15mg/L,
(ii) a total active joint count of at least 20 active
(swollen and tender) joints, or
(iii) at least 4 active joints from the following list of
major joints:
(a) elbow, wrist, knee, and/or ankle (assessed as
swollen and tender) and/or
(b) shoulder and/or hip (assessed as pain in passive
movement and restriction of passive movement, where
pain and limitation of movement are due to active
disease and not irreversible damage such as joint
destruction or bony overgrowth)
(i) currently taking methotrexate at a dose of
≥7.5mg/week (inﬂiximab and anakinra only),
(ii) failed to achieve an adequate response to
methotrexate at a dose of ≥20mg/week,
(iii) failed to achieve an adequate response to
methotrexate (≥7.5mg/week) with 2 other DMARDs at
approved doses,
(iv) failed to achieve an adequate response following a
minimum of 3 months treatment with Leﬂunomide
alone, or Leﬂunomide with methotrexate, or
Cyclosporin alone
Revision (ICD-9), is used to code site of malignancy [19]
and the ICD-O morphology rubrics to code histological type
[20, 21]. Cancer registration became mandatory nationally
(NCSCH) and in Victoria (VCR) in 1982. At the time of the
study the NCSCH and VCR were complete between 1982 to
2003 and 1982 to 2005, respectively.
Cancers prior to 1982 and after 2003/2005 for the
NBSCH and VCR, respectively, were veriﬁed by histology
report or conﬁrmation by the treating doctor. The date of
diagnosis of malignancy as recorded in the NCSCH and VCR
was used in the analysis if available. Otherwise the date of the
histology report or doctor veriﬁcation was used.
2.4. Representativeness of ARAD Participants. To examine
the extent to which ARAD includes a representative sample
of Australian RA patients taking bDMARDs, we surveyed
a random sample of 27 rheumatologists participating in
ARAD (20% of those participating in mid 2006). The
rheumatologists were asked to indicate whether all of their
patients receiving a bDMARD had been enrolled in ARAD
and reasons for nonenrolment.
2.5. Data Analysis. Responses to the health related quality of
life instruments (SF-36, AQoL, EuroQoL, and HAQ) were
coded according to the standard published algorithms as
described by the developers [14–17]. Descriptive statistics
were used for baseline characteristics and logistic regression
was used to determine whether rheumatologists with a
higher number of patients enrolled in ARAD were more
likely to have enrolled all of their bDMARD patients. All
data were analysed using SPSS for Windows, version 15.0
(Chicago, IL, USA).
3. Results
There were 681 RA patients who had taken bDMARDS
and enrolled in ARAD between 1st September 2001 and 1st
October 2006. bDMARDs prescribed were etanercept (n =
382, 56.1%), adalimumab (n = 253, 37.2%), inﬂiximab (n =
39, 5.7%) and anakinra (n = 7, 1.0%). Fifty-seven (8.4%)
RA patients had enrolled in ARAD after commencement of
bDMARDs and were therefore not able to be included in this
analysis.
The baseline demographic and disease characteristics
and health-related quality of life data for the remaining
624 (91.6%) patients are outlined in Table 2. Mean (SD)
age of the cohort was 57.0 (12.5) years and 449 (72.0%)
were female. At the time of commencement of bDMARDs,
572 (91.7 %) patients were receiving at least one DMARD
(Table 2), most commonly methotrexate (60.1%), and 420
(67.3%) participants were taking prednisolone (or pred-
nisone). Disease-speciﬁc and generic health-related quality
of life was signiﬁcantly impaired (Table 2).
At baseline, 56.8% of the cohort reported at least one
comorbid condition with 23.9% reporting two and 6.1%
reporting three or more. The most frequently self-reported
past or current comorbidities (occurring in a ﬁfth or more
of the cohort) were hypertension (40.7%), osteoporosis
(31.0%), hypercholesterolemia (26%), gastrointestinal dis-
ease (20.4%), eye disease (20.3%) and depression (19.6%)
(Table 3).
Sixty-ﬁve out of 624 participants (10.4%) had a ver-
iﬁed history of malignancy prior to commencement of
bDMARDs. These included nonmelanoma skin (n = 78
in 39 participants), breast (n = 6), cervix (n = 5), bowel
(n = 3), prostate (n = 3), melanoma (n = 3), lip (n = 1),
lung (n = 1), myeloma (n = 1), uterus (n = 1), testis
(n = 1)andvagina(n = 1).Themediantimebetweencancer
diagnosis and starting biologics was 7.8 years (range 21 days
to 33.5 years).
One hundred and thirteen (71.5%) participants reported
an infection in the 6 months prior to commencing
bDMARDs (Table 4). Kidney/bladder/urine and bone/joint/
muscle were the most commonly aﬀected sites for severe
infections and skin/nail and eye/ear/nose/throat the most
commonly reported sites for mild and moderate infections.
Thirteen of the 27 rheumatologists (48%) responded to
the representativeness survey. They had collectively enrolled
138 patients to ARAD. Five (38.5%) had enrolled all their
patients receiving bDMARDs to ARAD (n = 78 (56.5%)).
The remaining 8 rheumatologists identiﬁed 47 patients
receiving bDMARDs whom they had not enrolled. Of these,
12 (25.5%) were deemed unsuitable to participate either due4 International Journal of Rheumatology
Table 2: Baseline demographic and disease characteristics of the
ARAD RA cohort (n = 624)∗.
Mean (SD)
Age (years) 57.0 (12.5)
Duration of RA (symptoms), years 16.0 (11.0)
Duration of RA (since diagnosis), years 14.4 (10.2)
ESR (mm/hr) 35.8 (26.8)
CRP (mg/L) 33.7 (38.2)
PBS tender/swollen joint count# 23 (12)
Overall pain due to arthritis in last week
(0–100)
44.0 (25.8)
Overall patient global impression of disease
activity in the last week (0–100)
42.0 (25.3)
Mean (SD) HAQ score (0–3, 0 no = disability)
(n = 617)
1.8 (0.72)
Mean (SD) AQoL score (0-1, 1 = full health)
(n = 613)
0.42 (0.24)
SF-36 score (0–100, 100 = perfect health)
(n = 583)
Physical component 28.05 (9.88)
Mental component 43.66 (12.57)
EuroQoL (UK weights) (0-1, 1 = perfect
health) (n = 592)
0.46 (0.32)
N (%)
Female 449 (72)
Smoking history
Current 101 (16.2)
Past 266 (42.6)
Never 257 (41.2)
Alcohol consumption
Never 178 (28.9)
Sometimes 373 (60.7)
Every day 64 (10.4)
At least one concomitant DMARDs 572 (91.7)
Methotrexate (oral or IM) 375 (60.1)
Salazopyrin 73 (11.7)
Leﬂunomide 166 (26.6)
Hydroxychloroquine 115 (18.4)
Cyclosporin 16 (2.6)
Azathioprine 9 (1.4)
Gold 8 (1.3)
Penicillamine 4 (0.6)
Currently taking prednisolone or prednisone 420 (67.3)
∗n slightly diﬀerent for some variables.
#Pharmaceutical Beneﬁts Scheme (PBS) deﬁnition (see Table 1).
to sickness (n = 1) or inadequate English/literacy skills
(n = 11); 19 (40.4%) had been invited to participate but
declined; 16 (34.0%) were not enrolled due to other reasons
(rheumatologist time constraints or hospital initiated ther-
apy (n = 9), ARAD not discussed with the patient (n = 1),
patient overseas (n = 1); patient undecided at the time of
Table 3: Frequency of self-reported current and past comorbidities
among rheumatoid arthritis patients commencing bDMARD (n =
624)∗#.
N (%)
High blood pressure 254 (40.7)
Osteoporosis∗ 49 (31.0)
High blood cholesterol or lipids∗ 41 (26.0)
Gastrointestinal disease 127 (20.4)
Eye disease∗ 32 (20.3)
Depression∗ 31 (19.6)
Neurological disease∗ 27 (17.1)
Anaemia or blood disease 78 (13.5)
Diabetes 64 (10.3)
Heart attack or angina∗ 16 (10.0)
Lung disease 55 (8.8)
Thyroid∗ 10 (6.3)
Other heart disease (eg valve problems) 38 (6.1)
Coronary artery bypass
graft/angioplasty/stent∗ 8 (5.1)
Mental illness other than depression 18 (2.9)
Liver disease 17 (2.8)
Stroke/Transient Ischaemic Attack (TIA)∗ 4 (2.5)
Kidney disease 13 (2.1)
Drug or alcohol abuse 6 (0.9)
Tuberculosis∗ 1 (0.6)
Veriﬁed malignancy 65 (10.4)
Number of participants reporting an infection
within 6 months prior to commencing
biological therapy∗
113 (71.5)
∗n = 58 for conditions indicated with an asterisk.
#Listed in order of descending frequency.
the survey (n = 5). Having more patients enrolled in ARAD
was not associated with a higher odds of having enrolled all
patients in ARAD (Odds Ratio 1.10 (95% CI 0.96 to1.25)).
4. Discussion
Our study has found that more than half of the RA patients
who commence bDMARD therapy in routine care report
having at least one comorbid condition while almost a
quarter report having two or more. While it is not possible to
directly compare comorbidity results between studies due to
variability in deﬁning comorbidity, the conditions included
and the mode of data collection in the studies, our results are
broadly consistent with previous reports of baseline status
in other cohorts commencing biological therapy [2, 22, 23].
For example, the British Society for Rheumatology Biologics
Registry (BSRBR) reported that 58% of the RA cohort had
least one comorbid condition and 25% had more than one
[22]. Similar results were reported in a Dutch cohort of
RA patients taking bDMARDs (56% and 28%, resp.) [2].
On the other hand a lower proportion of patients (10.2%)
were found to have a baseline concurrent medical conditionInternational Journal of Rheumatology 5
Table 4: Self-reported infections and their severity∗ within the six
months prior to commencing bDMARDs (n = 158).
Mild Moderate Severe
Skin or nail 16 (10.1) 14 (8.9) 8 (5.1)
Eye, ear, nose, throat 9 (5.7) 23 (14.6) 4 (2.5)
Heart 1 (0.6) 1 (0.6) 0 (0)
Chest or lung 2 (1.3) 7 (4.4) 1 (0.6)
Stomach, gut, gall bladder, liver 2 (1.3) 2 (1.3) 3 (1.9)
Kidney, bladder, urine 3 (1.9) 12 (7.6) 7 (4.4)
Bone, joint, muscle 0 (0) 5 (3.2) 6 (3.8)
Artiﬁcial joint 0 (0) 0 (0) 1 (0.6)
Brain or spinal cord 1 (0.6) 0 (0) 0 (0)
Blood 0 (0) 2 (1.3) 2 (1.3)
Viral 5 (3.2) 9 (5.7) 2 (1.3)
Other 0 (0) 2 (1.3) 4 (2.5)
Total infections 39 (24.7) 77 (48.7) 38 (24.0)
∗Deﬁnitions of infection grades:
Mild: activities did not change because of complaint, did not see a doctor or
require prescription treatment for the complaint;
Moderate: activities changed occasionally because of the complaint, saw a
doctor and/or needed prescription medications to relieve the complaint;
Severe: caused a major change in activities, saw a doctor, required prescrip-
tion medication which only provided partial relief; if a drug treatment was
responsible it may have been stopped.
in a Swedish cohort commencing bDMARD therapy [24]
although these data were derived solely from the Swedish
National Hospital Discharge Register and so are likely to be
an underestimate.
We were unable to compare our baseline comorbidity
results with the characteristics of RA patients who have
participated in randomised controlled trials as these trials do
not report baseline comorbidities as a matter of routine and
in any case comorbidities are often an exclusion criterion.
However Zink et al. found that only 21–33% of RA patients
from the German biologics register Rheumatoid Arthritis
Observation of Biologic Therapy (RABBIT (in German))
would have been eligible for the major biologic trials that led
to approval of the drugs [25]. Similarly, Sokka and Pincus
estimated that only 5% of patients typically seen in practice
would be eligible for inclusion into a bDMARD RCT [26].
The high prevalence of multiple medical conditions
in RA patients commencing bDMARDs is likely to be
multifactorial, including the eﬀects of the disease and
medications used to treat the disease. The most commonly
reported medical conditions in RA patients commencing
bDMARDs in our sample were hypertension, osteoporosis
and depression. This is consistent with the BSRBR which
found that hypertension and depression were the most
common comorbidities present at baseline in RA patients
commencing bDMARDs [22]. Hypertension has also been
reported to be commonly present in cohorts of North
American and Dutch patients commencing bDMARDs [2,
27] and depression is known to be a common consequence
of rheumatoid arthritis [28, 29].
The overall prevalence of veriﬁed malignancy in
our population-based cohort prior to commencement of
bDMARDs (10.4%) is higher (1.5–3.0%) [2, 22, 27]o r
comparable (11.1%) [30], to previous population-based
studies of RA but higher than the 3% reported in the BSRBR
for people with RA commencing bDMARDs [2, 22, 27]. The
most common malignancy was nonmelanoma skin cancers
(n = 35)andtherewerealsothreeveriﬁedmelanomas.While
we cannot determine whether this is higher than would
be expected in the general population, an increased risk of
skin cancer in individuals with RA relative to the general
population has been reported previously [31]. The relative
risk of skin cancer in patients with RA compared with the
Swedish population was reported to be 1.66 (95% CI 1.50–
1.84) [31]. Notably, after treatment with TNF inhibitors, the
risk increased to 3.6 (95% CI 1.8–6.5).
The prevalence of skin cancers in our cohort may also
reﬂect the fact that Australia has the highest incidence of
both melanoma and nonmelanoma skin cancersin the world
[12]. For example, in 2002 nearly 2% of the whole Australian
population, 4% aged ≥40 years and 8% aged ≥70 years,
were treated for nonmelanoma skin cancer [32]. There were
a substantial number of self-reported malignancies we were
unable to verify for reasons such as they had occurred too
long ago and/or the records were no longer available. These
included 56 nonmelanoma skin cancers (some of which
may have been removed without histological veriﬁcation),
suggesting that the estimated prevalence of skin cancers (and
possible other malignancies) may be an underestimate. All
new self-reports of skin cancer are now being systematically
veriﬁed by histology and/or doctor report. This will provide
important data about nonmelanoma skin cancer risk in RA
patients exposed to biologics not available by any other
means as these are not routinely notiﬁed to the Australian
state cancer registries.
We have previously reported an estimated 50% excess
risk of malignancy amongst RA patients exposed to
methotrexate relative to the general population (SIR = 1.5,
95% CI 1.2–1.9) [33]. We followed 459 methotrexate-treated
RA patients in community practice in Melbourne Australia
for a total of 4273 person-years (an average of 9.3 years)
and relative to the general population found an increased
risk of melanoma (SIR = 3.0, 95% CI 1.2–6.2) as well as
nonHodgkin’s lymphoma (SIR = 5.1, 95% CI 2.2–10.0) and
lung cancer (SIR = 2.9, 95% CI 1.6–4.8). Further serial
record linkage of ARAD to the Australian National Cancer
Statistics Clearing House is planned to study melanoma and
other cancer incidence and reoccurrence rates in the ARAD
bDMARD cohort compared with the Australian general
population over time and compared with an ARAD non-
bDMARD control group.
Infections of any severity in the 6-month period prior
to commencing bDMARDs were reported by the majority
(71.5%) of our sample. It is important to note that our
severity grades diﬀer from those of regulatory clinical
trials and were speciﬁcally developed for patient self-report
[18]. Moderate-grade infections were reported most com-
monly, involving predominantly the ear, nose and throat or
skin/nails, while severe infections more commonly involved6 International Journal of Rheumatology
the skin/nails and genitourinary and musculoskeletal sys-
tems.Anincreasedriskofseriousinfectionhasbeenreported
among cohorts of patients receiving bDMARDs [9, 23]a n d
the sites of serious infection observed in our cohort are
similar to those reported in RA patients receiving bDMARD
therapy [23]. Our baseline infection data collected prior
to commencement of bDMARDs will enable comparison
to the rates and types of infection that occur following
commencement of bDMARDs.
This paper is the ﬁrst comprehensive description of
comorbidities, including a history of infection and malig-
nancy, among Australian patients with RA commencing bio-
logical therapy. Although the report characterises the proﬁle
of comorbidities among this population, our conclusions are
limited by the lack of comparison with people with RA who
are not receiving bDMARDs. At the present time, there are
too few ARAD participants with RA who have not received
a bDMARD to allow meaningful comparison. A further
potential limitation of our study is that we did not verify the
validityofpatientself-reportofcomorbidities.Theformatin
which possible comorbidities and infections were presented
to ARAD participants is identical to how they are presented
in this paper. We cannot be certain that ARAD participants
understood every comorbidity and infection category. Fur-
thermore, infection categories were not mutually exclusive,
so participants were able to mark more than one infection
which may have led to an overestimation of infection rates.
Despite these questionnaire limitations, previous studies
have found that self-report of comorbidities is reliable [34,
35]. Moreover, our earlier pilot investigations also provide
some evidence of the validity of self-report among ARAD
participants [36]. A ﬁnal limitation is that we cannot be
certain whether ARAD participants are representative of
Australian patients who commence bDMARDs. Incomplete
case ascertainment is an important consideration for data
validity and generalisability of health registries. Where
possible, all cases for a condition should be included in the
registry to minimise the threat of selection bias which may
skew results. Based upon the small sample of participating
rheumatologists that were surveyed as part of this study,
it appears that the majority of patients deemed suitable
for ARAD enrolment are being invited to participate. This
was recently veriﬁed in another survey we performed to
assess patient and rheumatologist satisfaction with ARAD
[37]. Further eﬀorts are being directed towards assisting
participating rheumatologists with patient enrolment to
maximise case ascertainment and enhance the validity of the
registry dataset.
5. Conclusion
Comorbidity is common among Australian patients with
RA taking bDMARDs. This is an important consideration
when evaluating the outcomes of bDMARD therapy and
assigning attribution of adverse events. More than 70%
of Australian RA patients commencing bDMARD therapy
reported a history of infection in the 6 months preceding
commencement of biologic therapy and 10% of patients
initiating bDMARD therapy in Australia have a veriﬁed
history of malignancy. Longitudinal follow up of these
patients will be important to study the eﬀects of bDMARDs
on risk of cancer recurrence.
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